How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction? | Synapse
April 10, 2026Open Access
How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?
Key Points
The study aims to explore how to personalize the delivery of botulinum toxin-A for optimizing treatment of neurogenic lower urinary tract dysfunction.
Examined various neurologic etiologies affecting treatment response
Evaluated the functional status of patients prior to treatment
Developed individualized treatment strategies based on assessment results
Individualized treatment strategies led to better health outcomes
Tailoring therapy improved patient satisfaction
Greater effectiveness observed in patients with specific neurologic conditions
Abstract
BoNT-A is an established therapy for NLUTD. Individualized treatment strategies that account for patients' neurologic etiology and functional status are beneficial in optimizing outcomes.